This most recent twist within the Lykos Therapeutics saga threatens A serious overhaul of the corporate’s approach and course, with Musk ally and billionaire investor Antonio Gracias showing to wish to choose the corporation back again toward its nonprofit drug growth roots and a far more Doblinite philosophy.And also to be reasonable, it’s not